VRAX
HEALTHCAREVirax Biolabs Group Ltd - Class A
$0.13+0.00 (+3.53%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving VRAX Today?
No stock-specific AI insight has been generated for VRAX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.10$1.20
$0.13
Fundamentals
Market Cap$935,350
P/E Ratio—
EPS$-1.22
Dividend Yield—
Dividend / Share—
ROE-0.8%
Profit Margin—
Debt / Equity—
Trading
Volume1.5M
Avg Volume (10D)—
Shares Outstanding7.4M
VRAX News
13 articles- Virax Biolabs' CEO James Foster Outlines Strategic Priorities and Near-Term Milestones in Letter to ShareholdersYahoo Finance·Apr 14, 2026
- Virax Biolabs Group Limited (VRAX) Upgraded to Buy: Here's WhyYahoo Finance·Jan 15, 2026
- Virax Biolabs Group Limited Announces Closing of $5 Million Private PlacementYahoo Finance·Dec 4, 2025
- Virax Biolabs Group Limited Announces $5 Million Private PlacementYahoo Finance·Dec 3, 2025
- BC-Most Active StocksYahoo Finance·Dec 3, 2025
- Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to ShareholdersYahoo Finance·Dec 3, 2025
- Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection SyndromesYahoo Finance·Nov 3, 2025
- Virax Biolabs (VRAX) Falls 18% on Lack of LeadsYahoo Finance·Aug 27, 2025
- Virax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early SeptemberYahoo Finance·Aug 26, 2025
- EXCLUSIVE: Virax Biolabs Inks Research Pact To Advance Long COVID Diagnostic StudiesYahoo Finance·Aug 26, 2025
- Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial StrategyYahoo Finance·Jul 29, 2025
- Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price DeficiencyYahoo Finance·Jul 18, 2025
- Virax Biolabs Group Full Year 2025 Earnings: Misses ExpectationsYahoo Finance·Jul 4, 2025
All 13 articles loaded
Price Data
Open$0.00
Previous Close$0.12
Day High$0.00
Day Low$0.00
52 Week High$1.20
52 Week Low$0.10
52-Week Range
$0.10$1.20
$0.13
Fundamentals
Market Cap$935,350
P/E Ratio—
EPS$-1.22
Dividend Yield—
Dividend / Share—
ROE-0.8%
Profit Margin—
Debt / Equity—
Trading
Volume1.5M
Avg Volume (10D)—
Shares Outstanding7.4M
About Virax Biolabs Group Ltd - Class A
Virax Biolabs Group Limited, a biotechnology company, sells, distributes and markets diagnostic test kits and medical technology products and PPE for the prevention, detection, diagnosis and risk management of viral diseases in the field of immunology. The company is headquartered in London, the United Kingdom.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—